| 查看: 238 | 回复: 0 | |||
村口一蹲木虫 (正式写手)
无
|
[交流]
【求助】求助哈，帮帮忙，求全文
|
|
1、Diabetes Care. 2009 Jul;32(7):1237-43. Epub 2009 Apr 14. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. 2、Horm Metab Res. 2009 Dec;41(12):905-9. Epub 2009 Aug 24. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes. 3、Horm Metab Res. 2009 May;41(5):368-73. Epub 2009 Feb 16. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy 4、Horm Metab Res. 2008 Dec;40(12):892-5. Epub 2008 Aug 22. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. 5、Horm Metab Res. 2007 Mar;39(3):218-23. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. 6、Horm Metab Res. 2006 Jun;38(6):423-8. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. 7、Diabetes Care. 2005 Aug;28(8):1936-40. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. 8、Horm Metab Res. 2008 Jun;40(6):427-30. Epub 2008 Mar 11.（已经找到全文） Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. |
回复此楼» 猜你喜欢
有没有人能给点建议
已经有3人回复
-
假如你的研究生提出不合理要求
已经有12人回复
-
实验室接单子
已经有7人回复
-
全日制（定向）博士
已经有5人回复
-
萌生出自己或许不适合搞科研的想法，现在跑or等等看？
已经有4人回复
-
Materials Today Chemistry审稿周期
已经有4人回复
-
参与限项
已经有3人回复
-
对氯苯硼酸纯化
已经有3人回复
-
所感
已经有4人回复
-
要不要辞职读博？
已经有7人回复
